Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

282
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
282
Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

60
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
60
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

45
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
45
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

597
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
597

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute cerebral infarction caused by severe anaphylactic shock: A case report.

Journal of anesthesia and translational medicine·2026
Same author

Border-Associated Macrophages in CNS Health and Disease: A Comprehensive Review of Ontogeny, Heterogeneity, and Functional Plasticity at Neural Interfaces.

ASN neuro·2026
Same author

Baicalein activates the type I interferon signaling pathway to inhibit infectious bronchitis virus infection.

Poultry science·2026
Same author

Stabilizing O3-type layered oxide cathodes <i>via</i> dual-site co-doping for long-life sodium-ion batteries.

Chemical science·2026
Same author

LlR3MYB-mediated flavonoid biosynthesis confers cold stress tolerance in <i>Lilium lancifolium</i> through the LlDREB-LlCHS2 regulatory cascade.

Horticulture research·2026
Same author

Association of Umbilical Cord Blood P-Selectin and PTX3 Levels with Early-Onset Sepsis in Preterm Infants with Premature Rupture of Membranes.

International journal of general medicine·2026

Related Experiment Video

Updated: Jun 7, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials.

Yingjie Qiu1,2, Mingyue Li1

  • 1Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Pharmaceutical Statistics
|November 11, 2024
PubMed
Summary
This summary is machine-generated.

Project Optimus aims to reform chemotherapy dosing. This study introduces a Bayesian adaptive design for oncology trials, integrating toxicity and efficacy to identify optimal doses (OD) and improve drug development.

Keywords:
Bayesian methodPhase I/II trialadaptive designdelayed outcomesmodel selectionoptimal dose

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K

Related Experiment Videos

Last Updated: Jun 7, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K

Area of Science:

  • Oncology Drug Development
  • Clinical Trial Design
  • Biostatistics

Background:

  • The traditional "more is better" chemotherapy dosing paradigm is outdated with new targeted therapies and antibody-drug conjugates (ADCs).
  • The US Food and Drug Administration (FDA) launched Project Optimus to address dose optimization and selection in oncology drug development.
  • Early-phase oncology trials face challenges due to data variability and rigid parametric models.

Purpose of the Study:

  • To develop a novel adaptive clinical trial design for optimizing dose selection in early-phase oncology studies.
  • To simultaneously incorporate both toxicity and efficacy data for robust optimal dose (OD) identification.
  • To enhance the design's adaptability for delayed toxicity and efficacy outcomes.

Main Methods:

  • Utilized Bayesian dynamic models to leverage information across different dose levels with minimal assumptions.
  • Employed Bayesian model averaging to manage uncertainties in dose-response relationships.
  • Developed an adaptive design integrating toxicity and efficacy for optimal dose selection in Phase I/II trials.

Main Results:

  • The proposed Bayesian adaptive design demonstrated desirable operating characteristics across various simulated scenarios.
  • The method effectively integrates toxicity and efficacy data for robust optimal dose identification.
  • The design proved adaptable to scenarios involving delayed toxicity and efficacy outcomes.

Conclusions:

  • The proposed Bayesian adaptive design offers a robust and flexible approach to optimal dose selection in oncology drug development.
  • This method addresses limitations of traditional dosing paradigms and supports Project Optimus' goals.
  • The design provides a practical framework for Phase I/II oncology trials, as illustrated by a trial example.